Daptomycin
Cyclic lipopeptide antibiotic
Also Cubicin, Cubicin RF, LY146032, Daptomycin for injection
- Evidence
- AStrong human evidence
- FDA status
- FDA approvedas of 2026-10-27
- Route
- Intravenous
- Studies cited
- 2 human0 animal or cell
Sold for
Daptomycin is a hospital antibiotic with no wellness market; its reputation is as a reliable option for MRSA bloodstream infections when vancomycin fails or cannot be used.
Studies say
A 246-patient randomized trial showed daptomycin cures S. aureus bacteremia and right-sided endocarditis about as often as standard therapy with less kidney damage, which with the skin-infection trials behind its approval supports an A.
Why grade A. Approval rested on randomized trials against standard antibiotics. The bacteremia and endocarditis trial in the citations randomized 246 patients and found daptomycin non-inferior to standard therapy, with success in 44.2% versus 41.7% at 42 days after treatment, a low absolute rate that reflects how hard these infections are to cure. 12
FDA. Daptomycin is FDA-approved as Cubicin (2003) and generics for complicated skin and skin-structure infections caused by susceptible Gram-positive bacteria and for Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis. It is not approved for pneumonia. 2
Written from 3 cited sources. Fact-checked 2026-10-27: 17 claims checked, 1 corrected. Last refreshed 2026-10-27. Not physician reviewed.
Evidence checklist
- Randomised controlled trial Randomized vs standard antibioticsyes
- Human study over 100 people Bacteremia trial, 246 patientsyes
- More than one research group Trials plus Spanish cohort of 617 patientsyes
- Clinical outcomes, not surrogate markers Treatment success at 42 daysyes
- Human safety data beyond case reports Muscle and lung effects well documentedyes
Drawn from the cited studies below. A dash means the sources give no information.
What it is
Daptomycin is a cyclic lipopeptide antibiotic: a ring of 10 amino acids with a three-amino-acid tail capped by a decanoic fatty acid, produced by the soil bacterium Streptomyces roseosporus. The FDA approved Cubicin in September 2003. 2
It is given only by intravenous infusion, and generic versions are available. 2
How it works
Daptomycin's fatty tail inserts into the bacterial cell membrane in a calcium-dependent way. The molecules cluster, distort the membrane and let potassium ions leak out, which collapses the electrical gradient the cell needs and kills it quickly without lysing it. This is a different target from the cell-wall synthesis blocked by vancomycin and the beta-lactams, so daptomycin retains activity against many vancomycin-resistant strains. It is inactivated by lung surfactant, which is why it does not work in pneumonia. 2
What human research shows
Fowler and colleagues randomized 246 patients with S. aureus bacteremia, with or without endocarditis, to daptomycin or to standard therapy (an anti-staphylococcal penicillin or vancomycin, each with initial low-dose gentamicin). The primary endpoint was treatment success 42 days after the end of therapy. Success was 44.2% with daptomycin (53 of 120) and 41.7% with standard therapy (48 of 115), an absolute difference of 2.4 percentage points with a confidence interval that met the non-inferiority margin. The bacteremia and endocarditis indication was added on the strength of this trial. 12
Clinically significant kidney dysfunction occurred in 11.0% of daptomycin patients against 26.3% on standard therapy, a difference largely attributed to the gentamicin and vancomycin in the comparator arm. Daptomycin did not establish non-inferiority in the small subgroup with left-sided endocarditis, and the label does not cover that use. 12
The two randomized skin-infection trials behind the 2003 approval, summarized on the label, showed clinical success rates comparable to vancomycin or penicillins. 2
The left-sided endocarditis gap has since been studied observationally. A Spanish nationwide prospective cohort followed 617 consecutive patients with left-sided endocarditis from methicillin-resistant staphylococci between 2008 and 2023, of whom 421 were treated mainly with daptomycin and 196 with vancomycin. Adjusted in-hospital mortality was similar, while adverse drug reactions were less frequent on daptomycin (14.5% versus 26.0%), mostly because of less acute kidney injury (8.7% versus 16.8%). The study is not randomized, so the comparison can be confounded by who was chosen for each drug. 3
| Study | Model | Finding |
|---|---|---|
| Fowler 2006, S. aureus bacteremia and endocarditis | Humans, n=246, randomized open-label non-inferiority trial | Success 44.2% with daptomycin versus 41.7% with standard therapy; kidney dysfunction 11.0% versus 26.3%. 1 |
| Cubicin prescribing information (skin infection trials) | Humans, two randomized trials versus vancomycin or penicillins | Clinical success comparable to comparators in complicated skin and skin-structure infections. 2 |
Safety
The signature adverse effect is muscle toxicity: creatine phosphokinase (CPK, a muscle enzyme) rises in a minority of patients and symptomatic myopathy or, rarely, rhabdomyolysis can follow, so the label calls for weekly CPK monitoring and more often in people with kidney impairment or on statins. Eosinophilic pneumonia, a drug-induced lung inflammation that usually appears two to four weeks into treatment, is a recognized rare reaction. Other common effects are diarrhoea, headache, insomnia and raised liver enzymes. 21
In the bacteremia trial, treatment failure with emergence of reduced daptomycin susceptibility occurred in some patients, mostly those with deep infections that were not drained. Resistance remains uncommon but is monitored. 12
Questions for your clinician
- Is daptomycin suited to the site of my infection, such as the heart valves or lungs?
- How often will my muscle enzymes be checked during treatment?
- Do my statin or kidney problems change this choice?
Questions people ask
Is daptomycin FDA-approved?
Yes. Cubicin was approved in 2003 for complicated skin infections and later for S. aureus bloodstream infections including right-sided endocarditis. Generics are available. 2
Why is it not used for pneumonia?
Lung surfactant binds and inactivates daptomycin, so it fails in pneumonia even against susceptible bacteria. The label excludes that use. 2
What was the success rate in the bacteremia trial?
About 44% at 42 days after treatment, against 42% for standard therapy. The rates look low because the endpoint demanded documented cure without relapse in a hard-to-treat infection, and they were similar in both arms. 1
What is the main side effect?
Muscle toxicity. Creatine phosphokinase is checked weekly, and the drug is stopped if it rises sharply or muscle pain develops. Eosinophilic pneumonia is a rarer but serious reaction. 2
Citations
- Fowler 2006, NEJM: daptomycin versus standard therapy for bacteremia and endocarditis caused by S. aureus doi.org
- Cubicin (daptomycin for injection) prescribing information merck.com
- Calderón-Parra 2026, Clin Microbiol Infect: daptomycin versus vancomycin in methicillin-resistant staphylococcal left-sided endocarditis, nationwide prospective cohort pubmed.ncbi.nlm.nih.gov
Updates
- 2026-10-27 added Spanish nationwide prospective cohort of daptomycin vs vancomycin in left-sided MRS endocarditis (n=617, similar mortality, fewer adverse reactions; PMID 42097302) to human findings.